Anti-hepatoma effect of taccalonolide A through suppression of sonic hedgehog pathway
Source abstract
Abstract
Taccalonolide A has been reported to have anti-tumour efficiency. However, the underlying mechanism for taccalonolides A therapy of hepatocellular carcinoma (HCC) is still obscure. Cell viability was evaluated by cell counting kit-8 (CCK-8) assay. Apoptosis was determined by flow cytometry. Protein expression of B cell lymphoma (Bcl-2), Bcl-2 associated X (Bax), sonic hedgehog (Shh), Smoothened (Smo) and Gli family zinc finger 1 (Gli1) was analyzed by western blot. The expression of Shh, Smo and Gli1 mRNA was determined using quantitative real-time polymerase chain reaction (qRT-PCR). Results showed that taccalonolide A inhibited cell proliferation, induced apoptosis and cell cycle arrest at the G0/G1 phase, and improved the cytotoxicity of sorafenib in HCC cells. The expressions of Shh, Smo, Gli1 mRNA and protein were decreased after taccalonolide A treatment. More importantly, activation of the Shh pathway attenuated taccalonolide A-induced inhibition on cell viability and promotion on apoptosis and cell cycle arrest in HCC. Also, activation of the Shh pathway neutralized the effect of taccalonolide A on sorafenib cytotoxicity in HCC. We clarified that taccalonolide A suppressed cell viability facilitated apoptosis, and improved the cytotoxicity of sorafenib in HCC by inhibition of the activation of the Shh pathway, providing alternative treatments for HCC.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hedgehog Signaling Pathway Studies · Cancer-related Molecular Pathways · Epigenetics and DNA Methylation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Infectious Disease, Huaihe Hospital of Henan University
References (34)
Show source-provided references
1. 10.1016/j.biopha.2019.10885910.1016/j.biopha.2019.108859 ↗
2. 10.1016/j.ebiom.2018.12.05810.1016/j.ebiom.2018.12.058 ↗
3. 10.1038/nature0933910.1038/nature09339 ↗
4. 10.1007/s10147-018-1312-510.1007/s10147-018-1312-5 ↗
5. 10.1007/s11010-018-3341-910.1007/s11010-018-3341-9 ↗
6. 10.1177/101042831881146710.1177/1010428318811467 ↗
7. 10.1002/pca.261910.1002/pca.2619 ↗
8. Tinley TL, Randall-Hlubek DA, Leal R, et al. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res. 2003;63:3211–3220.
9. 10.3389/fimmu.2014.0031610.3389/fimmu.2014.00316 ↗
10. 10.1016/j.canlet.2009.09.02010.1016/j.canlet.2009.09.020 ↗
11. 10.1021/jm200757g10.1021/jm200757g ↗
12. 10.1158/0008-5472.CAN-08-203710.1158/0008-5472.CAN-08-2037 ↗
13. 10.1016/j.intimp.2018.09.00910.1016/j.intimp.2018.09.009 ↗
14. 10.3389/fimmu.2018.0284710.3389/fimmu.2018.02847 ↗
15. 10.3892/etm.2016.396910.3892/etm.2016.3969 ↗
16. 10.1186/s12964-018-0220-710.1186/s12964-018-0220-7 ↗
17. 10.1016/j.jcyt.2017.05.00310.1016/j.jcyt.2017.05.003 ↗
18. 10.1002/jcp.2823110.1002/jcp.28231 ↗
19. 10.1042/BJ2015082110.1042/BJ20150821 ↗
20. 10.4161/cc.10.13.1623810.4161/cc.10.13.16238 ↗
21. 10.1021/acs.jnatprod.8b0103610.1021/acs.jnatprod.8b01036 ↗
22. 10.1021/acs.jnatprod.6b0094410.1021/acs.jnatprod.6b00944 ↗
23. 10.1021/jm500619j10.1021/jm500619j ↗
24. 10.1016/j.molmed.2010.05.00310.1016/j.molmed.2010.05.003 ↗
25. 10.1038/nrm162210.1038/nrm1622 ↗
26. 10.1016/j.fertnstert.2018.02.13810.1016/j.fertnstert.2018.02.138 ↗
27. 10.1016/j.gene.2018.06.01210.1016/j.gene.2018.06.012 ↗
28. 10.1093/abbs/gmy04510.1093/abbs/gmy045 ↗
29. 10.1002/cbin.1096510.1002/cbin.10965 ↗
30. 10.1002/jcb.2727710.1002/jcb.27277 ↗
31. 10.1245/s10434-012-2593-y10.1245/s10434-012-2593-y ↗
32. 10.12659/MSM.91476810.12659/MSM.914768 ↗
33. 10.1177/153473541558355310.1177/1534735415583553 ↗
34. 10.1186/1471-2407-14-72910.1186/1471-2407-14-729 ↗